AbbVie, Thermo Fisher Scientific And A Must-Watch Biotech ETF: CNBC's 'Final Trades'

On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said she is sticking with AbbVie Inc. ABBV, which has a 7.3% free cash flow yield and a dividend of over 3%. They innovate in immunology and oncology, she added.

Analysts have a consensus Outperform rating on ABBV, according to Benzinga's analyst ratings data.

AbbVie said it sees FY23 adjusted earnings of $10.62 to $11.02 per share, versus analysts’ estimates of $11.07 per share.

Karen Firestone of Aureus Asset Management named another healthcare name, Thermo Fisher Scientific Inc TMO, saying that this is a stock that peaked in December 2021. They can "now start to outperform big time," she added.

Barclays analyst Luke Sergott maintained Thermo Fisher Scientific with an Overweight and lowered the price target from $660 to $625.

Don’t forget to check out our premarket coverage here

Joseph Terranova of Virtus Investment Partners picked iShares Biotechnology ETF IBB as his final trade.

Price Action: Thermo Fisher Scientific shares rose 0.6% to close at $579.86, while AbbVie rose 0.6% to settle at $160.80 on Wednesday.

Check This Out: These 3 Consumer Stocks With Over 5% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts

Photo: Shutterstock